B. Riley Estimates Inogen's Q2 Earnings (NASDAQ:INGN)

Inogen, Inc (NASDAQ:INGN - Free Report) - Equities research analysts at B. Riley issued their Q2 2025 earnings per share estimates for shares of Inogen in a research report issued on Sunday, June 15th. B. Riley analyst A. Schock anticipates that the medical technology company will post earnings per share of ($0.22) for the quarter. B. Riley has a "Buy" rating and a $14.00 price objective on the stock. The consensus estimate for Inogen's current full-year earnings is ($1.73) per share. B. Riley also issued estimates for Inogen's Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($0.95) EPS, Q1 2026 earnings at ($0.22) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.72) EPS.

A number of other analysts have also recently issued reports on INGN. Needham & Company LLC upgraded Inogen from a "hold" rating to a "moderate buy" rating and set a $12.00 price objective on the stock in a research report on Thursday, May 22nd. Wall Street Zen downgraded shares of Inogen from a "buy" rating to a "hold" rating in a research note on Wednesday, February 26th. Finally, Stifel Nicolaus dropped their price objective on shares of Inogen from $10.00 to $7.00 and set a "hold" rating for the company in a research note on Thursday, May 8th.

Inogen Trading Up 1.9%

INGN traded up $0.12 on Wednesday, hitting $6.60. 140,538 shares of the stock traded hands, compared to its average volume of 241,418. The business has a fifty day moving average price of $6.66 and a two-hundred day moving average price of $8.30. The firm has a market capitalization of $177.47 million, a PE ratio of -5.74 and a beta of 1.64. Inogen has a 52 week low of $5.70 and a 52 week high of $13.33.

Inogen (NASDAQ:INGN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The medical technology company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.27. The company had revenue of $82.28 million for the quarter, compared to the consensus estimate of $79.57 million. Inogen had a negative net margin of 8.08% and a negative return on equity of 14.76%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. AlphaQuest LLC acquired a new position in Inogen in the fourth quarter worth $43,000. Meeder Asset Management Inc. bought a new position in shares of Inogen in the fourth quarter valued at about $56,000. Integrated Wealth Concepts LLC bought a new position in shares of Inogen in the first quarter valued at about $85,000. Algert Global LLC acquired a new position in Inogen during the 1st quarter worth about $89,000. Finally, Integrated Quantitative Investments LLC bought a new stake in Inogen during the 4th quarter worth about $92,000. 89.94% of the stock is owned by institutional investors.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.